Purchase this article with an account.
KIM SEEUN, JUNG HEUM HONG, SI DONG KIM, YOON YOUNG KIM; Risk factors for hydroxychloroquine retinopathy in the Korean population.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1837.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Several studies have reported risk factors for hydroxychloroquine (HCQ) retinopathy, but data are limited for patients of Asian ancestry. The aim of this study was to investigate the rate of and factors for HCQ retinopathy in the Korean population.
There were 123 patients enrolled in this study who were using or had used HCQ. Retinopathy was detected using spectral domain optical coherence tomography, fundus autofluorescence, multifocal electroretinography, and automated visual field testing. Binary logistic regression analysis was performed to identify factors associated with HCQ retinopathy.
Mean duration of HCQ use and mean HCQ dose in study participants was 10.1 years and 6.4 mg/kg, respectively. We found 17 patients (13.8%) with HCQ retinopathy among 123 patients. Patients with retinopathy took HCQ ranging from 6.7–21.9 years and daily dosage ranging from 4.9–9.1 mg/kg. Only 1 patient had retinal toxicity among patients with daily dose < 5.0 mg/kg. These factors increased the risk of HCQ retinopathy: longer duration of HCQ use [adjusted OR (aOR) = 4.71, 95% CI 2.18–10.15 for duration of HCQ use in 5-yr increments], higher daily HCQ dose (aOR = 3.34, 95% CI 1.03–10.80 for daily HCQ dose in 100-mg increments), and the presence of kidney disease (aOR = 8.56, 95% CI 1.15–64.00).
HCQ retinopathy is associated with duration of HCQ use, daily HCQ dose, and presence of kidney disease. Proper dosing of maximum 5 mg/kg and regular screening according to risk factors are important in HCQ use.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only